BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240709
DTEND;VALUE=DATE:20240712
DTSTAMP:20260515T195726
CREATED:20240319T002431Z
LAST-MODIFIED:20240319T003018Z
UID:38869-1720483200-1720742399@www.pharmajournalist.com
SUMMARY:3rd In Vivo Cell Engineering & Gene Editing Summit
DESCRIPTION:Welcome to the Future of Cell & Gene Therapy \nThe 3rd In Vivo Cell Engineering & Gene Editing Summit is an annual event uniting C-level in vivo experts to facilitate safe and targeted in vivo delivery of payloads while providing clarity in regulations and appropriate models to advance the next frontier of in vivo editing from research to clinic. \nExplore the full agenda – https://ter.li/snxcxi \nAs promising pre-clinical and proof of concept results continue to emerge\, the ‘dream’ of in vivo cell engineering and gene editing is rapidly becoming a reality as numerous companies push towards the clinic. \nJoin us this July to network with and gain invaluable knowledge from our world-class speaker faculty from Capstan Therapeutics\, Editas Medicine\, NanoCell Therapeutics\, Carisma Therapeutics\, Sanofi\, and more\, offering exclusive insights into their strategies for staying ahead of the curve and shaping the future of cell and gene therapy in the years ahead. \nKey Highlights: \n\nExploring data-driven case studies to outline decision making when selecting viral versus non-viral vectors\nClarifying regulatory expectations for this novel therapeutic approach to map out the future of your pipeline\nBenchmarking appropriate preclinical models to support translation to gain valuable data needed by regulatory bodies\nOutlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks\nEmphasizing target specificity and the mitigation off-site toxicities to ensure safety is front of mind in development\n\nRegister now for the best savings – https://ter.li/ssnrpz \n#InVivoCellEngineeringandGeneEditingSummit
URL:http://www.pharmajournalist.com/event/3rd-in-vivo-cell-engineering-gene-editing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR